ArticleBMC neurology2025
Post-stroke fatigue: The role of comorbidities and its impact on quality of life.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Latent Profiles of Post-Stroke Fatigue and Their Association with Anxiety, Depression, and Sleep in Patients with First-Ever Stroke: A Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2026Article
- Trajectories of post-stroke fatigue and its influencing factors in young and middle-aged patients with intracerebral hemorrhage.Frontiers in neurology · 2026Article
- A multicenter clinical nomogram for predicting post-stroke fatigue: development and validation.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPost-stroke fatigue (PSF) is a common complication following stroke that affects approximately 50% of stroke survivors. PURPOSE: The purpose of this study was to investigate the role of comorbidities in PSF and the impact of PSF on Quality of Life (QoL). To achieve this, residual stroke symptoms have also been considered.
methodsThe participants were stroke survivors living in a Swedish municipality. Self-reported data were collected via the Fatigue Assessment Scale (FAS), the Riksstroke questionnaire, and the Short Form Health Survey 36 (SF-36). Linear multiple regression and Spearman's correlation coefficient were used to analyze the data.
resultsA total of 142 participants (83 men) with a mean age of 74.8 (SD 9.7) years were included in the study. Fatigue levels were classified as normal (FAS 10-21) for 70 (49.3%) individuals, mild-to-moderate (FAS 22-34) for 56 (39.4%) individuals, and severe (FAS 35-50) for 16 (11.3%) individuals. The mean FAS score was 23.3 (SD 8.2). Multiple regression analysis indicated that the presence of vertigo (β = 0.24, p = 0.004), chronic pulmonary disorders (β = 0.29, p = 0.003), and hemiparesis (β = 0.18, p = 0.05) were associated with more severe PSF. The model explained 19.2% of the variance in PSF. A higher level of PSF was associated with worse QoL in all eight SF-36 domains (r = -0.38 to -0.67).
conclusionsVertigo, chronic pulmonary disorders, and hemiparesis were significantly associated with more severe PSF. Additionally, higher levels of fatigue were associated with a worse QoL. These findings confirm that PSF is a multifaceted phenomenon, underscoring the importance of addressing PSF in rehabilitation to improve outcomes for stroke survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.